Trade Names:Amikin- Injection 250 mg/mL- Pediatric injection 50 mg/mL
Inhibits production of bacterial protein, causing bacterial cell death.
Rapidly absorbed. C max is 12 to 21 mcg/mL (250 to 500 mg doses). T max is 1 h.IV
Single doses (500 mg over 30 min) produced C max 38 mcg/mL.
Vd is 24 L and protein binding is 0% to 11%. Crosses the placenta.
98.2% is excreted in the urine as unchanged drug within 24 h.IV
94% is excreted in the urine within 24 h. T 1/2 is about 2 h. Serum Cl is 100 mL/min; renal Cl is 94 mL/min.
Rate of excretion is decreased and t 1/2 is prolonged. Dosage adjustment may be needed.
Treatment of infections caused by susceptible strains of microorganisms, especially gram-negative bacteria.
Generally not indicated for long-term therapy because of ototoxicity and nephrotoxicity.
IV/IM 15 mg/kg (ideal body weight)/day in 2 or 3 divided doses. Treatment in heavier patients should not exceed 1.5 g/day.Uncomplicated utis
IV/IM 250 mg twice daily.Newborns
IV/IM Loading dose of 10 mg/kg is recommended followed by 7.5 mg/kg q 12 h. Lower doses may be needed in first 2 wk of life.
Store at 20° to 25°C (68° to 77°F).
May increase risk of nephrotoxicity.Loop diuretics (eg, furosemide)
May increase risk of auditory toxicity.Neuromuscular blocking agents (eg, tubocurarine)
Amikacin may enhance effects of these agents.
Do not mix with betalactam antibiotics (eg, carbenicillin, ticarcillin).
None well documented.
Hearing loss; deafness; loss of balance.
Oliguria; proteinuria; increased serum creatinine; urinary casts; red and white blood cells in urine; azotemia.
Decreased serum magnesium.
Manifests as both auditory and vestibular ototoxicity, and primarily occurs in patients with pre-existing renal damage or with prolonged therapy. Partial or total irreversible deafness may continue to develop after drug is stopped. Other features of neurotoxicity include paresthesias, twitching, and seizures.Nephrotoxicity
Teratogenic in pregnancy.
Renal and eighth nerve function closely monitored in patients with suspected renal dysfunction. Monitor peak and trough concentrations.
Dosage adjustments required in renal function impairment.
Neuromuscular blockade and respiratory paralysis have been reported following use of aminoglycosides. The possibility of these phenomena should be considered if aminoglycosides are administered by any route, especially in patients receiving anesthetics; neuromuscular blocking agents or in patients receiving massive transfusions of citrate-anticoagulated blood.
Category D .
Cautious use is necessary in premature infants and newborns because of renal immaturity.
Dosage adjustment is needed in patients with this condition.
Copyright © 2009 Wolters Kluwer Health.